Dr. Pierre Laneuville CML Chronic Myeloid Leukemia
Dr. Pierre Laneuville is an Associate Professor in the Department of Medicine and Oncology at McGill University and the former Head of Hematology for the McGill University Health Center. He is best known for his research on the molecular mechanisms underlying the genesis and transformation of chronic myelogenous leukemia.
VIDEOS
PCR and monitoring CML , ( Introduction PCR and monitoring CML Conclusion )
June 24, 2010, CML Society of Canada
PCR and monitoring CML , ( Introduction PCR and monitoring CML Conclusion )
June 24, 2010, CML Society of Canada
ARTICLES
The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up
November 13, 2019, ASH2019
Thrilled parents of MUHC’s first baby of 2019 boost umbilical cord blood bank
January 2, 2019, Montreal Gazette
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
March 8, 2018, Current Treatment Options in Oncology
Stopping second-generation TKIs in CML
February 16, 2017, Journal Blood
High Risk of Error in Categorizing Treatment Response in Individual CML Patients by Standard Cytogenetic Analysis or PCR Assay with High CV: A Bayesian Analysis
December 10, 2012, ASH 2012
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011, 2011 ASCO Annual Meeting
Umbilical cord blood: Making Every Drop Count
August 1st, 2011, McGill University Health Centre
MUHC Clinical Research Cord Blood Bank partners with the Public Cord Blood Bank of Héma-Québec
June 22nd, 2009, McGill University Health Centre
The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up
November 13, 2019, ASH2019
Thrilled parents of MUHC’s first baby of 2019 boost umbilical cord blood bank
January 2, 2019, Montreal Gazette
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
March 8, 2018, Current Treatment Options in Oncology
Stopping second-generation TKIs in CML
February 16, 2017, Journal Blood
High Risk of Error in Categorizing Treatment Response in Individual CML Patients by Standard Cytogenetic Analysis or PCR Assay with High CV: A Bayesian Analysis
December 10, 2012, ASH 2012
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011, 2011 ASCO Annual Meeting
Umbilical cord blood: Making Every Drop Count
August 1st, 2011, McGill University Health Centre
MUHC Clinical Research Cord Blood Bank partners with the Public Cord Blood Bank of Héma-Québec
June 22nd, 2009, McGill University Health Centre